Vasohibin 2 Promotes Lymphangiogenesis of Lung Squamous Cell Carcinoma Through Snail-dependent VEGF-D Signaling Pathway

Pengpeng Liu  
Tianjin Medical University Cancer Institute and Hospital: Tianjin Tumor Hospital

Rui Zhang  
Tianjin Medical University Cancer Institute and Hospital: Tianjin Tumor Hospital

Lei Han  
Tianjin Medical University Cancer Institute and Hospital: Tianjin Tumor Hospital

Xiao Zhang  
Tianjin Medical University Cancer Institute and Hospital: Tianjin Tumor Hospital

Yingnan Ye  
Tianjin Medical University Cancer Institute and Hospital: Tianjin Tumor Hospital

Wenwen Yu  
Tianjin Medical University Cancer Institute and Hospital: Tianjin Tumor Hospital

Xiubao Ren  
Tianjin Medical University Cancer Institute and Hospital: Tianjin Tumor Hospital

Weijia Zhang  
Icahn School of Medicine at Mount Sinai

Jinpu Yu (jyu@tmu.edu.cn)  
Tianjin Medical University Cancer Institute and Hospital: Tianjin Tumor Hospital

Research

Keywords: Vasohibin 2, Lymphangiogenesis, LUSC, Snail, VEGF-D

DOI: https://doi.org/10.21203/rs.3.rs-125315/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Tumor metastasis is a process in which tumor cells enter the lymphatic vessels and blood vessels and then spread to the secondary site where they form secondary tumors. In vascular biology, angiogenesis and anti-angiogenesis therapy have been extensively studied, however, the molecular mechanisms involved in lymphangiogenesis and lymphatic metastasis remain unclear.

**Methods:** We analyzed mRNA expression profiles of 937 primary lung squamous cell carcinoma (LUSC) samples from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases to screen the most differentially expressed genes related to the poor prognosis of LUSC patients and validated in an independent Chinese LUSC cohort. We focused on *Vasohibin 2* (VASH2) and investigated its biological functions in LUSC proliferation, apoptosis, migration, invasion, as well as lymphangiogenesis by forced over-expressing VASH2 in LUSC cell line H520 *in vitro*. We also investigated the anti-tumor efficacy of VASH2 target treatment in LUSC xenograft-bearing mice models.

**Results:** We identified 12 genes closely related to poor prognosis of LUSC patients, among which VASH2 was validated in an independent Chinese LUSC cohort and displayed high potential of lymphatic metastasis. VASH2 promoted the proliferation and invasion of LUSC cells both *in vitro* and *in vivo*. Forced over-expression of VASH2 in LUSC cells promoted the amplification and tube-formation of human umbilical vein endothelial cells (HUVECs) and human lymphatic endothelial cells (HLECs) cells via up-regulating vascular endothelial growth factor-D (VEGF-D) production which could be reversed by Snail inhibition. Furthermore, blocking VASH2/VEGF-D signaling using specific antibodies dramatically inhibited tumor growth in mice by interfering proliferation of cancer cells and lymphangiogenesis in tumor tissues.

**Conclusion:** In conclusion, VASH2 facilitated lymphangiogenesis and tumor growth in a Snail-dependent manner which might serve as a novel biomarker for early diagnosis and prognosis prediction, as well as a potential therapeutic target in LUSC.

**Statement of conflict of interest:** The authors declare no potential conflicts of interest.

**Background**

Lung cancer is one of the most common human malignancies with high incidence and mortality worldwide [1]. The 5-year survival rate of lung cancer is only about 18.1% [2, 3], mainly due to its aggressive invasion and rapid progression [1]. Non-small cell lung cancer (NSCLC) accounts for the majority (>85%) of all lung cancers, among which lung squamous cell carcinoma (LUSC) accounts for about 30% cases but has little benefit from targeted therapies compared to lung adenocarcinoma (LUAD) for less druggable target biomarkers [4]. Thus, there is an urgent need to uncover the molecular mechanisms involved in aggressive invasion and metastasis of LUSC in order to develop novel therapeutic strategies with high efficiency for LUSC.
Invasion and metastasis are a complex dynamic process involved multiple factors, which mainly occurs through blood vessels and lymphatic vessels. In LUSC, some studies have illuminated lymphangiogenesis could enhance the affinity of tumor cells to lymphatic vessels, further promoting invasion and metastasis through lymphatic vessels [5]. However, the mechanisms of lymphangiogenesis in LUSC development and progression are still unclear. Considering LUSC metastasis initiated from invading into lymph nodes through lymphatic vessels [6, 7], specific interdiction of lymphangiogenesis would provide more efficient inhibition on LUSC invasion compared to routine anti-angiogenesis treatment. Therefore, to discriminate the key biomarkers regulating the process of lymphangiogenesis in LUSC will throw a light on developing novel anti-cancer therapeutic strategies for LUSC [8-10].

In previous study, we analyzed mRNA expression profiles of 937 primary LUSC samples from GEO and TCGA databases and filtered out VASH2 as one of the clinical beneficial predictable biomarkers associated with LUSC poor prognosis. The gene for human VASH2 is located on chromosome 1q32.3. The full-length human VASH2 is composed of 355 amino acid residues [11]. It was initially reported to be expressed in endothelial cells. VASH2 is mainly expressed in monocytes (MNCs), which are mobilized from bone marrow and infiltrated into the front of germination [12].

VASH2 has been demonstrated to be an angiogenic factor in a variety of tumors, including liver cancer, gastric cancer, breast cancer, and ovarian cancer [13-15], and plays an important role in tumor development [16]. However, none study on the expression and function of VASH2 in lung cancer, especially in LUSC has ever been reported. It has been reported that exogenous VASH2 significantly promoted tumor growth, increased microvessel density and hemoglobin concentration [17], while tumor angiogenesis was significantly inhibited in VASH2 knockout mice [18]. Furthermore, VASH2 was reported to trigger epithelial-mesenchymal transition (EMT), up-regulate chemotherapeutic resistance, and increase the proportion of cancer stem like cells [19, 20] which can generate cellular traits associated with more aggressive malignancy with higher motility and invasiveness by imparting the trait of self-renewal to cancer cells. However, whether VASH2 promotes invasion and metastasis of lung cancer is related to angiogenesis or EMT has not been disclosed.

In this study, we explored the clinical significance of VASH2 in LUSC, and potential molecular mechanisms involved in VASH2 promoting the development and progression of LUSC. We demonstrated that high level of VASH2 was significantly associated with poor prognosis and promoted lymphatic metastasis in patients with LUSC. It was confirmed from cell experiments and animal models that overexpression of VASH2 promoted angiogenesis and lymphangiogenesis, and accelerated the invasion and metastasis of tumor cells by stimulating EMT. The expression of VASH2 can significantly increase the production of Snail and VEGF-D in LUSC cells. And blocking VASH2/VEGF-D signaling pathway could significantly inhibited the growth of tumor and the formation of lymphatics. In summary, we not only revealed VASH2 as a marker of LUSC, but also proposed new molecular mechanisms of lymphatic metastasis, which provided potential molecular diagnosis and targeted treatment strategies for patients with LUSC.
Methods

Reagents and antibodies

RPMI1640 (C11875500BT), DMEM/F12 (11330032), fetal bovine serum (10099141), Trypsin (25200072) and antibiotic-Antimycotic (15240062) were purchased from Gibco BRL (Grand Island, NY, USA). FITC BrdU Flow kit (559619), Annexin-V-FITC Apoptosis Detection kit (556547) and Matrigel (356230) were purchased from BD Biosciences (San Jose, CA, USA). Trizol (15596026) were purchased from Invitrogen (Grand Island, NY, USA). ELISA kit to detect secretion of VEGF-D (ELH-VEGFD-001) was purchased from RayBiotech (Norcross, GA, USA). ELISA kit to detect secretion of VASH2 (ab155288) was purchased from Abcam (Cambridge, UK). DMSO (D2650) was purchased from Sigma (St. Louis, MO, USA). Oligo-(dT)15 primer, 10 mM dNTP, RNase inhibitor, SYBR Premix Ex Taq™ kit (RR820A) were purchased from Takara (Tokyo, Japan). In flow cytometry assay, all fluoresce-labeled antibodies were purchased from Biolegend (San Diego, CA, USA), including PE anti-human Podoplanin Lymphoendothelial cell surface markers (LEC), and PE-IgG1. In immunohistochemistry, all antibodies were purchased from Bioss (Beijing, China) and biotinylated secondary goat anti-mouse or rabbit IgG antibody was purchased from Santa Cruz (Dallas, TX, USA).

Mice

BALB/c female mice between 6-8-week-old were purchased from Beijing SPF Biotechnology Co., Ltd. Mice were maintained at SPF animal laboratory of Tianjin Medical University Cancer Hospital and Institute. To establish the lung adenocarcinoma mouse models, the mouse lung adenocarcinoma cells H520CTRL and H520OV-VASH2 (1×10⁶ cells in 100ul PBS) was injected into the mammary fat pads of BALB/c mice to induce tumor formation [1]. All procedures that involve mice were approved by the Ethics Committee for Animal Experiments at the Tianjin Medical University Cancer Hospital and Institute, and were performed in accordance with the Guide for the Care and Use of Laboratory Animals.

Cell Lines

Human lung adenocarcinoma cell line H520 was obtained from Chinese Academy of Medical Sciences tumor cell libraries.

Cell line culture

The human LUSC cell line H520 was cultured in RPMI 1640 complete medium containing 10% fetal bovine serum in at 37°C, 5% CO2. By transfecting wild-type H520 cells (H520CTRL) with VASH2-specific short hairpin RNA (shRNA) lentiviral vectors, H520OV-VASH2 cells were established as indicated in our previous work. Stably transfected cells were cloned by limiting dilution and validated using RT-PCR and Western blot as our previous work described.

Clinical samples
This study recruited 64 cases of LUSC patients treated with partial lung resection surgery at the Department of Hepatobiliary Oncology of the Tianjin Medical University Cancer Institute and Hospital from November 2004 to November 2006. These patients included 49 males and 19 females with a median age of 62.7 years. No prior treatments, including chemotherapy or radiotherapy, were conducted before lung resection surgery was performed. Postoperative follow-up time was 40–65 months. This project was approved by the Ethics Committee of Tianjin Medical University. All experiments were performed in accordance with the principles of the Declaration of Helsinki. Written consents were obtained from the patients. Tissue samples were flash frozen and stored at 80°C.

**Data Processing for Public Datasets**

Public datasets were downloaded from the GEO and TCGA database. 10 studies of LUSC expression profiling with a minimum of 24 LUSC patients were collected from GEO database for the meta-analysis study, including 41 dataset from GSE50081, 78 dataset from GSE41271, 55 dataset from GSE30219, 24 dataset from GSE19188, 72 dataset from GSE8894, 43 dataset from GSE42127, 53 dataset from GSE3141, 52 dataset from GSE14814, 66 dataset from GSE37745, 38 dataset from Tianjin database and 415 dataset from TCGA. Detailed information for these datasets is listed in Figure S1.

The workflow for the meta-analysis of the discovery set of 1 Tianjin and 10 public LUSC datasets was depicted in Figure S1. Meta genes associated with short survival (<5 years: 5 years was the median survival of 11 cohorts) and long survival (>5 years) were identified by a meta p-value of less than 0.05 by combining p values from 11 datasets and individual p value <0.05 in at least 4 out of 11 datasets from the 11 datasets. The meta genes were subjected to Gene Ontology (GO) and canonical pathway enrichment with multiple pathways databases (KEGG, Reactome, PID, Wiki Pathways, Biocarta and Panther).

**Immunohistochemistry**

All samples were heated for 0.5 h at 56°C, deparaffinized in xylene and rehydrated through graded alcohol. Antigens were retrieved by heating in citrate buffer (pH 6.0) for 20 min. Endogenous peroxidase activity was quenched in a bath of methanol and hydrogen peroxide for 30 min. The samples were then incubated overnight at 4°C with mouse antibody, and a biotinylated secondary goat anti-mouse or rabbit IgG antibody labeled with streptavidin-horseradish peroxidase (HRP) using a DAB staining kit according to the manufacturer’s instructions. Five representative high-power fields (400× magnification) were selected for each tissue section for histological evaluation. For each protein, two parameters, namely, positive rate (PR) and staining intensity (SI), were used to describe the expression on the basis of the extensity and intensity of the positively stained cells in the samples. PR denotes the percentage of positively stained cells in cancer tissues: ≤15%, negative (scored as 0); 16%–50%, positive at low frequency (scored as 1); 51%–80%, positive at medium frequency (scored as 2); and ≥80%, positive at high frequency (scored as 3). SI refers to the ranked staining intensity of positively stained cells in LUSC samples. This value ranged from 0 to 3, which corresponded to negative, weakly positive, moderately positive, and strongly positive. The sum represented the final scores of each protein marker in the
samples because protein expression was comprehensively evaluated on the basis of both parameters. A final score of <4 was defined as low/negative expression and a final score of ≥4 was defined as high expression.

**Lentivirus construction**

The vector pHBLV-CMV-MCS-3FLAG-EF1-ZsGreen-T2A-PURO was digested at 37°C and the gel was recovered. Then the fragments were recovered by PCR. The target fragment was connected with the vector and the reaction system (20ul). 100ul competent cell suspension was taken from -70°C refrigerator and thawed at room temperature. Add plasmid DNA solution, shake gently, place on ice for 30 minutes, heat shock in 42°C water bath for 90 seconds and quickly place on ice to cool for 3-5 minutes after heat shock. 1 ml LB liquid medium (without antibiotics) was added into the tube, and then it was stirred at 37°C for 1 hour in a 220 RPM shaker. The bacteria were restored to normal growth state and expressed antibiotic resistance gene encoded by plasmid. After shaking the above bacterial solution, centrifugation was performed to remove 900ul supernatant. After the remaining culture medium was sucked and mixed, 100ul was applied to the screening plate containing antibiotics. The plate was placed upside down for half an hour. After the bacterial solution was completely absorbed by the medium, the plate was inverted and cultured at 37°C for 16-24 hours. After the transformation, the plates were picked up and shaken for 14 hours at 230 RPM / min at 37°C. The positive clones were sent to sequencing company for sequencing for construction of VAHS2 and Snail overexpression lentivirus. The synthesized VASH2 shRNA and Snail shRNA were inserted into plvx-U6-CMV-RFP-P2A-BSD and pHBLV-U6-MCS-CMV-ZsGreen-PGK-PURO lentiviral vectors respectively. The lentivirus was generated as described above.

**Tube formation**

H520CTRL and H520OV-VASH2 cells were cultured as described above. When the cells reached 80% confluence, the culture medium was changed to DMEM without fetal bovine serum. After an additional 48h culture, the supernatant was collected as CM and stored at 20°C. After thawed at 4°C overnight, the Matrigel was coated in 96-well plate then incubated at room temperature for at least 30 min to gel. HUVECs or HLECs were suspended at a density of 2×10^5 cells/ml in the different CMs. The cell suspensions (100 ml) were added to each Matrigel coated well. DMEM was substituted for CM for the negative control. DMEM and VASH2 factor were substituted for CM for the positive control. After 18h, the formed networks were photographed and analyzed to calculate the formation rate of tubes was calculated according to the following equation: Formation rate (%) = Cell number_{Tube quantity}/Cell number_{Total}× 100%.

**RT-qPCR analysis for gene expression**

Total RNA was exacted using the Trizol kit according to the manufacturer’s protocol. Complementary DNA was synthesized using equivalent amounts of total RNA (1 μg) in a 20 μl reverse transcriptase reaction mixture and detected using SYBR Premix Ex Taq™ in 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). The primers were synthesized from Santa Cruz (Dallas, TX, USA). The sequences of
primers are shown in Table 2. All experiments were performed in triplicates and were calculated for \( \Delta CT \). 
\[
\Delta CT = CT_{\text{target gene}} - CT_{\text{reference gene}}
\]
And relative expression quantity of mRNA is \( 2^{-\Delta CT} \). Most of the PCR primer sequences used in this study were referenced from literatures (27-38). But for the primer sequences of 8 EMT-related genes (Zeb1, Zeb2, Twist1, Snail, Slug, β-catenin, N-cadherin and E-cadherin) and VEGF family genes (VEGF-A, VEGF-C and VEGF-D), they were designed by ourselves and validated in our previous work.

**Enzyme-linked immunosorbent assay (ELISA)**

Cells \( (4 \times 10^5) \) were seeded into 6-well plates and the culture supernatants of H520\(^{\text{CTRL}}\) and H520\(^{\text{OV-VASH2}}\) cells were collected after 48 h to determine the VASH2 and VEGF-D levels using the VASH2/VEGF-D ELISA kit.

**Western blot analysis**

The cells were harvested and washed twice with PBS (pH 7.4, 0.15 M). Total protein was extracted by RIPA buffer (Beyotime, Shanghai, China). Approximately 30 µg of total protein was subjected to SDS-PAGE and transferred to PVDF membranes. The membranes were blocked with 5% skim milk in TBST and incubated with the primary antibody (1:1000) in TBST containing 5% BSA overnight at 4 °C. The membranes were washed twice with TBST and incubated with HRP-conjugated secondary antibody (1:4000; Santa Cruz, Dallas, TX, USA) at room temperature for 2 h. The membrane was exposed using an enhanced chemiluminescence reagent (Chemicon International, USA). The membranes were then reprobed with anti-β-actin antibody (Santa Cruz, Dallas, TX, USA) in 1:2000 dilutions to confirm equal protein loading. The antibodies to detect VASH2, VEGF-D, Snail, and actin were purchased from Cell Signaling Technology (MA, USA).

**Cell counting kit-8 (CCK-8) assay**

Cells \( (8 \times 10^3) \) were seeded into 96-well plates. CCK-8 solution (10 µL; Dojindo Molecular Technologies, Inc., Rockville, MD, USA) was added to each well for different time periods (2, 24, 72, and 96 h) and incubated for 2 h at 37 °C. The cell viability was represented by the absorbance measured at 450 nm.

**Cell Apoptosis Analysis**

The apoptotic in H520\(^{\text{CTRL}}\) and H520\(^{\text{OV-VASH2}}\) cells was measured using Annexin-V-FITC. The Annexin-V-FITC Apoptosis Detection kit was used to measure apoptosis. After 12 hours starvation treatment, cells were washed with PBS and resuspended in 1×binding buffer at a concentration of 1×10^6 cells/ml. Subsequently, 5µl of Annexin-V and 10µl of PI were added to 100µl of the cell suspension, and the mixture was incubated for 15min in the dark. The analyses were performed using a flow cytometry. Because the growth factors were solved in DMSO for cell culture experiment, DMSO was added into medium and diluted at the final concentration of 5µg/ml, serving as a negative control in order to eliminate the disturbance of solvent. The experiments were repeated at least 3 times.
Wound Healing Assay

Cells were seeded into 6-well plates for 24h to reach 80~90% confluence. The cell monolayer was wounded in a straight line with a 10μl pipette tip to create a “wound”. Cell debris was removed by PBS and the wounded cells were cultured with fresh medium. Images were taken at 0, 24h and 48h later to measure the distance of the wound. The cell migration rate = (the distance of the wound at 0h - the distance of the wound at 24h or 48h) / the distance of the wound at 0h × 100%. The experiments were repeated at least 3 times.

Trans-well invasion assay

The Matrigel and Trans-well were used to carry out lung cancer cell invasion assays to build invading chambers for separating high invasive and low invasive cells. Cells were seeded at a density of 1×10^5 cells in the Matrigel and 100μl serum-free RPMI-1640 to the 24-well plate Trans-well system with an 8-μm pore size polycarbonate filter membrane (Coming, NY, USA). The lower chambers contained 10% FBS containing medium. The cells were incubated for 48h. The cells on the lower surface of the membrane were fixed with methanol and stained with 1% toluidine blue. The stained membranes were photographed through the microscope and invading cells were counted. The experiments were repeated at least 3 times.

In Vivo Tumorigenicity Study

H520^CTRL and H520^OV-VASH2 cells were collected and an equal number of 1×10^6 cells in 100μl of PBS were mixed with Matrigel respectively. The mixed cells were injected subcutaneously into both flanks of BALB/c mouse. The tumor sizes were monitored every 3 days. Each group contains 5 mice. And the experiments were repeated at least 3 times. The tumor volume (V) was calculated by the formula: V=3.14×L×W×H/6 (L: length, W: width, H: height). The animal protocol used in this study was approved by the Ethics Committee for Animal Experiments of the Tianjin Medical University Cancer Hospital and Institute, and was performed in accordance with the Guide for the Care and Use of Laboratory Animals.

Once palpable tumors were formed (in ~7–10 days) treatment cycles was initiated. The mice were anesthetized by intraperitoneal injection of 100 mg/kg anti-VEGFD and 10 mg/kg anti-VASH2. Treatment involved the mice being randomly divided into three groups, control, anti-VEGFD, and anti-VASH2—with each group containing 5 mice. The control group of mice were subjected to 1 × PBS injections also for 5 consecutive days. After the completion of the treatment cycle the mice were sacrificed and the tumors were excised. Tumor volumes for the excised tumors were measured using a caliper and volumes were calculated as previously mentioned. Tumors were then fixed and processed for immunohistochemistry.

Flow Cytometry

The concentration of antibodies used for staining and the time of co-incubation were followed the manufacturer’s instruction. PE anti-human Podoplanin antibody was used at the concentration of 12.5 μg/ml. 1×10^5 cells were resuspended in 100μl PBS, incubated for 30 min with different antibodies before
washing and being fixed using 4% paraformaldehyde. Since all protein markers are membrane proteins, none cells were permeabilized. The samples were analyzed by BD FACS Aria flow cytometer (BD Biosciences).

**Data Analysis and Statistical Methods**

Data were analyzed using SPSS 17.0. Quantitative data were presented as mean ± standard deviation. We performed Student’s t-test when analyzing the statistical comparisons between two groups. Meanwhile, for more than 2 groups included in this study, we used one-factor ANOVA assay to evaluate the difference among all groups, followed by LSD method to compare the difference between each 2 groups. Statistical significance was set at p<0.05.

**Results**

*High expression of VASH2 correlated with worse prognosis and more lymphatic metastasis in LUSC patients*

We collected and analyzed the global gene expression profiling of 937 primary LUSC tissue samples from 11 database based on the disparity in clinical outcomes. We defined the patients with a survival time more than 40 months as good prognosis group, and those with a survival time less than 40 months as poor prognosis group. And we identified 12 highly differentially expressed genes which significantly correlated with patients’ poor prognosis (Figure S1). We collected LUSC tissue samples from Tianjin Medical University Cancer Institute and Hospital (TJMUCH) to validate the correlation between the 12 identified genes and overall survival (OS) in 20 cases. The immunohistochemical (IHC) staining results and Kaplan-Meier survival analysis indicated that the patients with high expression of VASH2 and IL-33 showed a worse prognosis significantly (VASH2: 25.13±11.57 vs. 52.42±30.65 months, \( p = 0.023 \); IL-33: 30.55±8.39 vs. 50.45±21.18 months, \( p = 0.032 \); Figure 1A). Among them, Overexpression of VASH2 was significantly correlated with the poor prognosis in 4 of 11 databases, indicating that VASH2 is a novel prognostic factor of LUSC whose high expression was significantly correlated with comparably shorter OS in different databases (Figure 1B). The finding of TCGA data implied that VASH2, previously reported to be associated with angiogenesis, might be a potential prognosis predictive biomarker for LUSC which was significantly up-regulated in LUSC cases suffering from shorter OS.

In order to validate the correlation between VASH2 and clinical outcome in LUSC, we collected another independent cohort composing of 64 LUSC samples from TJMUCH. The mRNA level of VASH2 in LUSC samples was detected using real-time quantitative PCR (qPCR) assay. We observed that low VASH2 expression was mainly found in patients survived more than 40 months, while level of VASH2 mRNA of good prognosis group is much lower than that of poor prognosis group (10.68±1.13 vs. 10.14±0.96, \( p = 0.01 \); Figure 1C). In addition, we compared the level of VASH2 protein in the corresponding LUSC paraffin specimens using IHC analysis, and found that VASH2 protein was predominately higher in patients with short OS compared to that in patients with long OS (63.82±5.18% vs. 20.88±3.74%, \( p = 0.01 \), Figure 1D). Above results indicated that both the transcription and expression of VASH2 gene in LUSC are
significantly correlated with poor survival outcomes consistently. Furthermore, we analyzed the association between VASH2 and other clinicopathology and found that high expression of VASH2 positively corresponds with more lymph node metastasis, larger tumor size, and worse clinical stage (Figure 1E, Table 1). These results indicated that VASH2 was a valuable biomarker to predict poor prognosis and lymphatic metastasis in LUSC.

**VASH2 accelerated the proliferation and invasion potential of LUSC cells, and promoted tube-formation capacity of HUVEC and HLEC cells**

Then, the supernatants from cultures of H520CTRL and H520OV-VASH2 were collected. In order to investigate the underlying biological roles of VASH2 in carcinogenesis and lymphangiogenesis, VASH2 was up-regulated in LUSC cell line NCI-H520 cells by transfecting recombinant lentivirus (Figure S2A). High level of VASH2 was confirmed in the supernatants of H520OV-VASH2 compared to that in H520CTRL. The level of VASH2 protein in different supernatants was detected by ELISA. We found H520OV-VASH2 secreted more VASH2 than H520CTRL (602.75±73.84pg/ml vs. 196.39±38.29pg/ml, p=0.001, Figure 2A).

We first compared the proliferation and apoptosis of H520OV-VASH2 and found higher proliferation but lower apoptosis rates in H520OV-VASH2 compared to those in H520CTRL (72h: 3.42±0.43 vs. 2.19±0.36, p=0.044, Figure 2B). (6.94±1.68% vs. 15.23±0.98%, p=0.013, Figure 2C). The migration and invasion potentials were compared. The wound closure rates (WCRs) were significantly higher in H520OV-VASH2 cells and more H520OV-VASH2 migrated across the Matrigel layer after 48h (77.89±7.64% vs. 56.25±5.47%, p=0.016, Figure 2D), and (228.67±16.77 vs. 174.33±12.50, p=0.011, Figure 2E).

Next, HUVECs and HLECs were co-cultured with the supernatants from either H520OV-VASH2 or H520CTRL cells. The HUVECs and HLECs cultured in DMEM medium were used as negative controls. The numbers of forming tubes in each group were assessed. The results showed that when recombinant VASH2 was added to the supernatant, HUVECs and HLECs could form more tubes (HUVEC: 15.38±3.41% vs. 32.39±8.47, p=0.032; HLEC: 20.54±3.17% vs. 47.64±8.64%, p=0.007, Figure 2F-G). The typical tubule formation of HUVEC and HLEC cells was inhibited and reduced by adding specific VASH2 blocking antibody (HUVEC: 32.39±8.47% vs. 8.65±2.64%, p=0.0098; HLEC: 47.64±8.64% vs. 12.19±3.62%, p=0.0028, Figure 2F-G). The H520OV-VASH2 supernatant could stimulated both HUVEC and HLECs cells to generate comparable amount of tubes as recombinant VASH2 did in vitro, which was significantly higher than the H520CTRL supernatant did (HUVEC: 39.64±7.31% vs. 21.39±4.35%, p=0.021; HLEC: 43.67±7.64% vs. 14.67±5.37%, p=0.0058, Figure 2H-I). But after adding specific VASH2 blocking antibody, the typical tube formation of HUVEC cells was partly inhibited while the tube formation of HLECs was fully eliminated (HUVEC: 25.36±4.39% vs. 39.64±7.31%, p=0.043; HLEC: 16.23±8.73% vs. 43.67±7.64%, P=0.015, Figure 2H-I). Above results implied that VASH2 not only effectively promoted proliferation and invasion potential of LUSC cells, but also significantly enhanced lymphangiogenesis in vitro.

**VASH2 facilitated lymphangiogenesis via up-regulating VEGF-D production in LUSC cells**
In order to define the molecular events regulating VASH2-related lymphangiogenesis, the transcription and expression of lymphangiogenesis-related VEGF family members in H520\textsuperscript{OV-VASH2} cells, including VEGF-A, VEGF-C and VEGF-D, were measured using qPCR assay. No significant difference at the mRNA levels of VEGF-A and VEGF-C was detected between H520\textsuperscript{CTRL} and H520\textsuperscript{OV-VASH2} cells. But mRNA and protein level of VEGF-D in H520\textsuperscript{OV-VASH2} cells was significantly higher than that in H520\textsuperscript{CTRL} cells (p=0.008, p=0.046, Figure 3A-B). The level of VEGF-D protein in the supernatants of H520\textsuperscript{OV-VASH2} and H520\textsuperscript{CTRL} was compared by ELISA assay. We found H520\textsuperscript{OV-VASH2} secreted more VEGF-D than H520\textsuperscript{CTRL} (497.37±67.51pg/ml vs. 218.54±45.36pg/ml, p=0.023, Figure 3C). Furthermore, specific VEGF-D blocking antibody could efficiently inhibited the tube formation of HLECs co-cultured with H520\textsuperscript{OV-VASH2} (29.67±4.67 vs. 64.48±8.12, p=0.003, Figure 3D). These data implied that VASH2 over-expression promoted the production and secretion of VEGF-D in LUSC cells, which might directly facilitate VASH2-induced lymphangiogenesis \textit{in vitro}. VEGF-D antibody was added to the two groups of cells respectively. The effect of VEGF-D on VASH2 production and release was detected by ELISA and PCR. The level of VASH2 protein in the supernatants has no difference in H520\textsuperscript{OV-VASH2+VEGF-DAB} compared with H520\textsuperscript{OV-VASH2} (563.54±89.21pg/ml vs 592.72±60.34pg/ml, p=0.24, Figure 3E). There is still no difference in mRNA expression (6.83±1.64 vs 8.61±1.51, p=0.24, Figure 3F).

**VASH2 enhanced tumor proliferation and invasion via up-regulating Snail expression in LUSC cells**

The transcription of multiple EMT-related biomarkers was detected using qPCR assay, and we found that the level of Snail mRNA increased in H520\textsuperscript{OV-VASH2} compared to H520\textsuperscript{CTRL} but that of E-cadherin decreased which indicated VASH2 promoting EMT in LUSC cells. However, there was no significant difference of the mRNA levels of the mesenchymal cell biomarkers β-catenin and N-cadherin, and other EMT-related TFs, such as Zeb family (Zeb1 and Zeb2), Slug, and Twist1 (Figure 4A). These results implied that VASH2 promoted LUSC cell EMT by stimulating Snail transcription.

To further determine if VASH2 up-regulated LUSC cell proliferation and invasion via Snail, we further designed a recombinant lentivirus to knock down Snail in H520\textsuperscript{OV-VASH2} cells (H520\textsuperscript{OV-VASH2+sh-Snail}), as well as another recombinant lentivirus to force over-expression of Snail in wide-type H520 cells to establish H520\textsuperscript{OV-Snail} (Figure S2B-C). We compared the proliferation of H520\textsuperscript{CTRL}, H520\textsuperscript{OV-VASH2}, H520\textsuperscript{OV-VASH2+sh-Snail} and H520\textsuperscript{OV-Snail} cells using the CCK-8 staining assay and found that the proliferation rates were lower in H520\textsuperscript{OV-VASH2+sh-Snail} than that in H520\textsuperscript{OV-VASH2} (H520\textsuperscript{OV-VASH2+sh-Snail}: 2.51±0.38; H520\textsuperscript{OV-VASH2}: 3.97±0.52; H520\textsuperscript{CTRL}: 2.07±0.31, p=0.022, Figure 4B). And the proliferation rates were higher in H520\textsuperscript{OV-Snail} than that in H520\textsuperscript{CTRL} (4.14±0.52 vs. 2.36±0.38, p=0.031, Figure 4C). The cell migration and invasion were compared using the wound healing and trans-well assays. It showed that less H520\textsuperscript{OV-VASH2+sh-Snail} and more H520\textsuperscript{OV-Snail} migrated across the Matrigel layer compared with their control cells (H520\textsuperscript{OV-VASH2+sh-Snail}: 175.36±23.47; H520\textsuperscript{OV-VASH2}: 254.17±30.78; H520\textsuperscript{CTRL}:164.24±20.14, p=0.024, Figure 4D; 217.93±16.77 vs. 125.69±15.13, p=0.002, Figure 4E). The similar results were detected in wound healing assay (H520\textsuperscript{OV-VASH2+sh-Snail}:41.36±5.69%; H520\textsuperscript{OV-VASH2}: 69.64±7.15%; H520\textsuperscript{CTRL}:56.34±5.42%).
37.25±4.95%, p=0.005, Figure 4F; 85.32±8.47% vs. 34.25±5.68, p=0.001, Figure 4G). These results demonstrated that VASH2 promoted the proliferation and invasion of LUSC cells via up-regulating Snail transcription and expression.

**Snail regulated VASH2-related lymphangiogenesis via stimulating VEGF-D production in LUSC cells**

We found that VEGF-D was also up-regulated in samples with high expression of Snail in H520\textsuperscript{OV-VASH2} which implied a potential causal relationship between Snail and VEGF-D. Therefore, we first determined if Snail mediated VASH2-induced lymphangiogenesis. We transfected H520\textsuperscript{OV-VASH2} cells with sh-Snail recombinant lentivirus and compared the tube formation capacity of HLECs or HUVECs co-cultured with either H520\textsuperscript{CTRL}, H520\textsuperscript{OV-VASH2}, H520\textsuperscript{OV-VASH2+sh-Snail} or H520\textsuperscript{OV-Snail} cells. The number of HLEC-formed tubes in H520\textsuperscript{OV-VASH2+sh-Snail} group was less than that in H520\textsuperscript{OV-VASH2} group (40.67±6.43% vs. 64.67±7.67%, p=0.014, Figure 5A). However, there was no difference between the number of HUVEC-formed tubes in H520\textsuperscript{OV-VASH2} and H520\textsuperscript{OV-VASH2+sh-Snail} groups (28.54±3.64% vs. 37.64±5.79%, p=0.083, Figure 5B). Furthermore, when we transfected H520 cells with Snail recombinant lentivirus, and found that the number of HLEC-formed tubes in H520\textsuperscript{OV-Snail} group was higher than that in H520\textsuperscript{CTRL} group (85.32±8.47% vs. 34.25±5.68%, p=0.001, Figure 5C). There is still no difference in the HUVEC-formed tubes (20.98±4.23% vs. 27.36±6.71%, p=0.24, Figure 5D).

In order to determine if Snail regulated VASH2-stimulated VEGF-D production, H520\textsuperscript{CTRL}, H520\textsuperscript{OV-VASH2}, H520\textsuperscript{OV-VASH2+sh-Snail} and H520\textsuperscript{OV-Snail} cells were collected to compare the mRNA levels of VEGF-A, VEGF-C and VEGF-D at by qPCR assay. Compared to H520\textsuperscript{OV-VASH2}, a significant decrease of the mRNA level of VEGF-D in H520\textsuperscript{OV-VASH2+sh-Snail}, but no difference was detected in the mRNA levels of VEGF-A and VEGF-C (Figure 5E). Consistently, compared to H520\textsuperscript{CTRL}, over-expression of Snail induced a significant increase of VEGF-D at 6.47 folds rather than VEGF-A and VEGF-C (p=0.008, Figure 5F). Above results indicated that Snail regulated VASH2-related lymphangiogenesis rather than angiogenesis via stimulating VEGF-D production.

**VASH2 was significantly correlated with either Snail or VEGF-D in primary LUSC tissues**

The protein levels of Snail and VEGF-D in 64 cases of primary LUSC tissues were assessed using IHC staining assay (Figure 6A). We used qPCR to detect the mRNA levels of VASH2, Snail and VEGF-D in LUSC. Snail and VEGF-D were highly expressed in VASH2 overexpression samples, and VEGF-D was also highly expressed in snail overexpression samples (Figure 6B). In addition, the results of IHC were consistent with this result. The positive rate and intensity of Snail inVASH2-positiveLUSC tissues were higher than that in VASH2-negativeLUSC tissues (73.92±2.43% vs. 20.16±2.72%, p=0.019, Figure 6C). The similar results were observed in the average positive rate of VEGF-D (67.06±3.85% vs. 25.08±3.36%, p=0.035, Figure 6C). And among the Snail-positive LUSC patients, the average positive rate of VEGF-D was much higher than that in Snail-negative LUSC patients (61.74±4.19% vs. 20.98±2.87%, p=0.033, Figure 6C).
To further compare the correlation among VAHS2/Snail/VEGF-D and prognosis of patients with LUSC, we divided them into double positive group. We compared the OS between VASH2\(^+\)Snail\(^+\)LUSC patients and non-VASH2\(^+\)Snail\(^+\)patients, as well as between VASH2\(^+\)VEGF-D\(^+\) patients and non-VASH2\(^+\)VEGF-D\(^+\)patients. Kaplan–Meier survival analysis revealed that VASH2\(^+\)Snail\(^+\) patients suffered from shorter OS than non-VASH2\(^+\)Snail\(^+\) patients (17.21 ± 1.39 months vs. 70.75 ± 2.54 months, p=0.062, Figure 6D). Similarly, VASH2\(^+\)VEGF-D\(^+\) patients exhibited a shorter OS than non-VASH2\(^+\)VEGF-D\(^+\) patients (39.93 ± 5.46 months vs. 63.71 ± 3.27 months, p = 0.011, Figure 6D).

**VASH2 blocking antibody inhibited tumor growth and lymphangiogenesis by attenuating VEGF-D production**

H520\(^{-}\) and H520\(^{OV-VASH2}\) were injected at 1\(\times\)10\(^6\) tumor cells/100 \(\mu\)l per mouse subcutaneously into NOD-SCID mice. After 26 days, the average volumes of tumors generated in H520\(^{OV-VASH2}\) group were nearly 3-fold larger than those in H520\(^{-}\) group (1805.62±171.56mm\(^3\) vs. 648.64±92.21mm\(^3\), p=0.041, Figure 7A). The proportion of LYVE-1 positive cells referring to lymphoepithelial cells in H520\(^{OV-VASH2}\) was significantly higher than H520\(^{CTRL}\) (75.37±8.63\% vs. 4.26±0.74\%, p=0.001, Figure 7B), which indicated that VASH2 promoted the lymphangiogenesis in vivo.

In order to confirm if targeted therapy against either VASH2 or VEGF-D was efficient to inhibit tumor metastasis and local lymphangiogenesis in vivo, mice were treated with anti-VASH2 or anti-VEGF-D antibodies at a dose of 2.5mg/kg bodyweight by i.p. injection three times per week. We found the tumor sizes were significantly reduced after either treatment (H520\(^{OV-VASH2}\): 1805.62±171.56mm\(^3\), H520\(^{OV-VASH2+VASH2AB}\): 1105.36±92.21mm\(^3\), H520\(^{OV-VASH2+VEGF-DAB}\): 1281.36±215.36mm\(^3\), p<0.01, Figure 7A). Furthermore, after anti-VASH2 or anti-VEGF-D antibodies, the proportion of lymphoendothelial cells was significantly reduced by more than two times (H520\(^{OV-VASH2}\):75.37±8.63\%; H520\(^{OV-VASH2+VASH2AB}\): 31.86±4.14\%; H520\(^{OV-VASH2+VEGF-DAB}\): 26.73±3.27\%, p<0.01, Figure 7B). The similar results were observed by flow cytometry by labeling D2-40 positive cells, which is another marker of lymphoepithelial cells (H520\(^{OV-VASH2}\): 79.71±9.58\%; H520\(^{CTRL}\): 32.48±4.36\%; H520\(^{VASH2-VASH2Ab}\): 44.82±5.36\%; H520\(^{OV-VASH2+VEGF-DAB}\): 47.42±5.69\%, p<0.01, Figure 7C).

Then, we extracted tumor RNA and compared the mRNA levels of Snail and VEGF-D between different groups using qPCR assay. We noticed that the mRNA levels of above genes were significantly up-regulated in H520\(^{OV-VASH2}\) compared to H520\(^{CTRL}\), which was consistent with the observation in vitro. (Snail: 2.89±0.36, p=0.009; VEGF-D: 4.97±0.68, p=0.007, Figure 7D-E). We also noticed that the mRNA levels of Snail and VEGF-D were significantly down-regulated in H520\(^{OV-VASH2+VASH2AB}\) compared to H520\(^{OV-VASH2}\) (Snail: 0.79±0.11 vs 2.89±0.36, p=0.006; VEGF-D: 1.75±0.84 vs 4.97±0.68, p=0.006, Figure 7D-E). But the mRNA expression of Snail has no difference in H520\(^{OV-VASH2+VEGF-DAB}\) compared with H520\(^{OV-VASH2}\) (Snail: 2.48±0.19 vs 2.89±0.36, p=0.15; VEGF-D: 2.12±0.98 vs 4.97±0.68, p=0.014, Figure 7D-E). The same conclusion could be reached by detecting protein level by western blot. The protein
levels of Snail and VEGF-D in H520<sup>OV-VASH2</sup> was higher than that in H520<sup>CTRL</sup> Snail: 1.84±0.49 vs 1.13±0.095, p=0.044; VEGF-D: 1.49±0.64 vs 0.92±0.12, p=0.026, Figure 7D-E). The protein levels of Snail and VEGF-D were significantly decreased by adding VASH2 antibody (Snail: 0.57±0.094 vs 1.84±0.49, p=0.012; VEGF-D: 0.89±0.084 vs 1.49±0.64, p=0.017, Figure 7D-E). When VEGF-D antibody was added, the protein level of Snail had no difference (Snail: 1.52±0.28 vs 1.84±0.49, p=0.38; VEGF-D: 0.78±0.19 vs 1.49±0.64, p=0.013, Figure 7D-E).

**Discussion**

Although many studies have confirmed the predominant role of microvascular development, especially angiogenesis in tumor growth and metastasis, the anti-angiogenesis therapy has not achieved sufficient clinical efficacy as expected until now [21]. Actually, recent studies showed that the initial metastasis of most malignant tumors is not through blood vessels, but firstly through lymphatic vessels to local lymph nodes [22, 23]. Lymphangiogenesis, the development of new lymph vessels, has been reported to promote lymphatic invasion and lymph node metastasis. Therefore, anti-lymphangiogenesis therapy has become a relatively hot topic of clinical investigation and might be more promising strategy to inhibit the metastasis and spread of tumors in early stage.

In this study, based on 937 LUSC gene expression profiling data from 11 public datasets in GEO and TCGA dataset, as well as 64 LUSC primary tissues from TJMUCH independent cohort, we demonstrated that VASH2 was an independent prognostic biomarker for LUSC. We validated the positive correlation between VASH2 and poor prognosis of LUSC patients both at mRNA and protein levels. The IHC results of an independent Chinese LUSC cohort showed that there was no correlation between the expression of VASH2 and CD31 and other vascular endothelial markers, while the pathological analysis showed that the expression of VASH2 was significantly related to the number of lymph node metastasis in LUSC patients. Furthermore, we found that VASH2 expression was significantly positively correlated with the number of lymph node metastasis rather than distant metastasis. We indicated that VASH2 promoted amplification and tube-formation of HUVEC and HLEC cells, and accelerated proliferation and invasion of LUSC cells. Further studies demonstrated that VASH2 facilitated lymphangiogenesis via up-regulating VEGF-D production in LUSC cells and enhanced tumor proliferation and invasion via up-regulating Snail expression in LUSC cells.

VASH2 was reported as an angiogenic factor promoting tumor development and progression [13, 24]. VASH2 regulates the expression of VEGF through autocrine and paracrine mechanisms, and promotes angiogenesis [25]. VEGF family was identified as an endothelial cell-specific mitogen that has the capacity to induce physiological and pathological angiogenesis and lymphangiogenesis. Among the VEGF family members, VEGF-C and VEGF-D have similar structures, but bind and activate VEGF receptor VEGFR-2 and VEGFR-3, respectively. VEGF-C and VEGF-D promoted angiogenesis and lymphangiogenesis within and at the periphery of solid tumors, as well as enhancing solid tumor growth and metastatic spread to lymph nodes and distant organs [26, 27]. Actually, the understanding of the molecular mechanisms of VEGF-C in lymphatic development and lymphangiogenesis has been greatly appreciated
in multiple cancers, however, the role of VEGF-D is less well understood. Previous studies showed that VEGF-D could compensate for the loss of VEGF-C for the sprouting of lymphatics, indicating VEGF-D might play a subtler role in regulating lymphatic vascular development than VEGF-C [28-30]. In this study, we found VEGF-D was significantly up-regulated in H520OV-VASH2 cells, but the expression of VEGF-C did not change significantly, suggesting that VASH2 promoted lymphangiogenesis mainly through up-regulation of VEGF-D, but not VEGF-C signaling.

Snail has been reported to promote lymph node metastasis [31]. Snail is a transcription factor involved in EMT, but plays an important role in lymphatic metastasis, and increased lymph node metastasis. Consistently, we found that Snail positively correlated with the level of VASH2 and the status of lymph node metastasis. The relationship between Snail and lymphangiogenesis, as well as Snail and VEGF-D, are not fully investigated yet [32].

In this study, we found that Snail participated in VASH2-mediated lymphangiogenesis via up-regulation of VEGF-D in LUSC cells. Inhibition VEGF-D via anti-VEGF-D antibody could reduce tumor growth in vivo, not affecting Snail expression, which implied a “VASH2-Snail-VEGF-D” axis in promoting lymphangiogenesis and tumor progression in LUSC. Furthermore, we observed that inhibition of VASH2 showed better therapy effect than inhibition of VEGF-D in the mouse model, which is most likely due to the function of VASH2 monoclonal antibodies in interfering proliferation of cancer cells as well as lymphangiogenesis in tumor tissues simultaneously.

**Conclusion**

In conclusion, we found that the high expression of VASH2 was significantly related to the poor prognosis and lymph node metastasis of LUSC patients. VASH2 could increase the expression of VEGF-D, up-regulate the expression of Snail and down-regulate the expression of E-cadherin in LUSC cells, and promote the formation of lymphatics. Therefore, further investigations for a comprehensive understanding of VASH2 in tumor development will probably provide us more effective promising therapeutic strategies for treating metastatic disease.

**Abbreviations**

LUSC lung squamous cell carcinoma

TCGA The Cancer Genome Atlas

GEO Gene Expression Omnibus

VASH2 Vasohibin 2

HUVECs human umbilical vein endothelial cells
HLECs human lymphatic endothelial cells
VEGF-D Vascular endothelial growth factor-D
LUAD lung adenocarcinoma
MNCs monocytes
EMT epithelial-mesenchymal transition
OS overall survival
IHC immunohistochemical
qPCR quantitative PCR
WCRs wound closure rates
ELISA Enzyme-linked immunosorbent assay
CCK-8 Cell counting kit-8

Declarations

Ethics approval and consent to participate
This study was approved by the Ethics Committee of Tianjin Medical University. All experiments were performed in accordance with the principles of the Declaration of Helsinki and written consent was obtained from all patients.

Consent for publication
My material is original research, has not been previously published and has not been submitted for publication elsewhere while under consideration.

Availability of data and material
Not applicable

Competing interests
No conflict of interest exits in the submission of this manuscript, and manuscript is approved by all authors for publication. The work described was original research that has not been published previously, and not under consideration for publication elsewhere, in whole or in part. Consent for publication was obtained from all patients contained in our manuscript.
Funding

This work was supported by National Natural Science Foundation of China (grant numbers: 82072588, 82002601, 81872143, 81702280). National Science and Technology support Program of China (Grant No. 2018ZX09201015), Projects of Science and Technology of Tianjin (Grant No. 18JCQNJC82700) and Key project of Tianjin Health and Family Planning Commission (Grant No. 16KG126).

Authors' contributions

PPL performed data analyses, and wrote the manuscript. PPL, RZ and XZ performed the research jointly. LH performed bioinformatics analysis. YNY and XBR contributed clinical information and samples for the study. WZ gave guidance and help on the bioinformatics analysis. JPY designed the study and commented on manuscript.

References

1. Rafiemanesh H, Mehtarpour M, Khani F, Hesami SM, Shamlou R, Towhidi F, et al. Epidemiology, incidence and mortality of lung cancer and their relationship with the development index in the world. J Thorac Dis. 2016;8(6):1094-102.

2. Zakaria N, Yusoff NM, Zakaria Z, Lim MN, Baharuddin PJN, Fakiruddin KS, et al. Human non-small cell lung cancer expresses putative cancer stem cell markers and exhibits the transcriptomic profile of multipotent cells. BMC Cancer. 2015;15:84-.

3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA: a cancer journal for clinicians. 2009;59(4):225-49.

4. Patz EF, Jr., Greco E, Gatsonis C, Pinsky P, Kramer BS, Aberle DR. Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial. Lancet Oncol. 2016;17(5):590-9.

5. Hu JM, Liu K, Liu JH, Jiang XL, Wang XL, Yang L, et al. The increased number of tumor-associated macrophage is associated with overexpression of VEGF-C, plays an important role in Kazakh ESCC invasion and metastasis. Experimental and Molecular Pathology. 2017;102(1):15-21.

6. Mumprecht V, Detmar M. Lymphangiogenesis and cancer metastasis. Journal of cellular and molecular medicine. 2009;13(8A):1405-16.

7. Li S, Li Q. Cancer stem cells, lymphangiogenesis, and lymphatic metastasis. Cancer letters. 2015;357(2):438-47.

8. Ikemura S, Aramaki N, Fujii S, Kirita K, Umemura S, Matsumoto S, et al. Changes in the tumor microenvironmet during lymphatic metastasis of lung squamous cell carcinoma. Cancer Sci. 2017;108(1):136-42.

9. Moon Y, Park JK, Lee KY, Sung SW. Lymphatic invasion is a more significant prognostic factor than visceral pleural invasion in non-small cell lung cancer with tumours of 3 cm or less. Respirology.
10. Watabe T. Roles of transcriptional network during the formation of lymphatic vessels. The Journal of Biochemistry. 2012;152(3):213-20.

11. Sato Y. The vasohibin family: a novel family for angiogenesis regulation. J Biochem. 2013;153(1):5-11.

12. Koyanagi T, Suzuki Y, Komori K, Saga Y, Matsubara S, Fujiwara H, et al. Targeting human vasohibin-2 by a neutralizing monoclonal antibody for anti-cancer treatment. Cancer Sci. 2017;108(3):512-9.

13. Kitahara S, Suzuki Y, Morishima M, Yoshii A, Kikuta S, Shimizu K, et al. Vasohibin-2 modulates tumor onset in the gastrointestinal tract by normalizing tumor angiogenesis. Mol Cancer. 2014;13:99-.

14. Tu M, Lu C, Lv N, Wei J, Lu Z, Xi C, et al. Vasohibin 2 promotes human luminal breast cancer angiogenesis in a non-paracrine manner via transcriptional activation of fibroblast growth factor 2. Cancer letters. 2016;383(2):272-81.

15. Takahashi Y, Koyanagi T, Suzuki Y, Saga Y, Kanomata N, Moriya T, et al. Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis. Molecular cancer research : MCR. 2012;10(9):1135-46.

16. Kimura H, Miyashita H, Suzuki Y, Kobayashi M, Watanabe K, Sonoda H, et al. Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis. Blood. 2009;113(19):4810-8.

17. Koyanagi T, Saga Y, Takahashi Y, Suzuki Y, Suzuki M, Sato Y. Downregulation of vasohibin-2, a novel angiogenesis regulator, suppresses tumor growth by inhibiting angiogenesis in endometrial cancer cells. Oncol Lett. 2013;5(3):1058-62.

18. Heishi T, Hosaka T, Suzuki Y, Miyashita H, Oike Y, Takahashi T, et al. Endogenous angiogenesis inhibitor vasohibin1 exhibits broad-spectrum antilymphangiogenic activity and suppresses lymph node metastasis. Am J Pathol. 2010;176(4):1950-8.

19. Zhang Y, Xue X, Zhao X, Qin L, Shen Y, Dou H, et al. Vasohibin 2 promotes malignant behaviors of pancreatic cancer cells by inducing epithelial-mesenchymal transition via Hedgehog signaling pathway. Cancer Med. 2018;7(11):5567-76.

20. Xue X, Zhang Y, Zhi Q, Tu M, Xu Y, Sun J, et al. MiR200-upregulated Vasohibin 2 promotes the malignant transformation of tumors by inducing epithelial-mesenchymal transition in hepatocellular carcinoma. Cell Commun Signal. 2014;12:62-.

21. Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18(1):60-.

22. Pereira ER, Kedrin D, Seano G, Gautier O, Meijer EFJ, Jones D, et al. Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice. Science. 2018;359(6382):1403-7.

23. Stewart CL, Warner S, Ito K, Raoof M, Wu GX, Kessler J, et al. Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure? Curr Probl Surg. 2018;55(9):330-79.
24. Norita R, Suzuki Y, Furutani Y, Takahashi K, Yoshimatsu Y, Podyma-Inoue KA, et al. Vasohibin-2 is required for epithelial-mesenchymal transition of ovarian cancer cells by modulating transforming growth factor-β signaling. Cancer Sci. 2017;108(3):419-26.

25. Xue X, Gao W, Sun B, Xu Y, Han B, Wang F, et al. Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma. Oncogene. 2013;32(13):1724-34.

26. Choi JU, Chung SW, Al-Hilal TA, Alam F, Park J, Mahmud F, et al. A heparin conjugate, LHbisD4, inhibits lymphangiogenesis and attenuates lymph node metastasis by blocking VEGF-C signaling pathway. Biomaterials. 2017;139:56-66.

27. Alishekevitz D, Gingis-Velitski S, Kaidar-Person O, Gutter-Kapon L, Scherer SD, Raviv Z, et al. Macrophage-Induced Lymphangiogenesis and Metastasis following Paclitaxel Chemotherapy Is Regulated by VEGFR3. Cell Rep. 2016;17(5):1344-56.

28. Miyata Y, Matsuo T, Ohba K, Mitsunari K, Sakai H. 1135 CIGARETTE SMOKING INDUCES LYMPHANGIOGENESIS, BUT NOT ANGIGENESIS, AND VASCULAR ENDOTHELIAL GROWTH FACTOR-D, BUT NOT -A OR -C IN HUMAN BLADDER CANCER TISSUES. Journal of Urology. 2013;189(4):e463-e4.

29. Lin W, Jiang L, Chen Y, She F, Han S, Zhu J, et al. Vascular endothelial growth factor-D promotes growth, lymphangiogenesis and lymphatic metastasis in gallbladder cancer. Cancer letters. 2012;314(2):127-36.

30. Ebata R, Abe J, Yasukawa K, Hamada H, Higashi K, Suwazono Y, et al. Increased Production of Vascular Endothelial Growth Factor-D and Lymphangiogenesis in Acute Kawasaki Disease. Circulation Journal. 2011;75(6):1455-62.

31. Cho YA, Kim EK, Cho BC, Koh YW, Yoon SO. Twist and Snail/Slug Expression in Oropharyngeal Squamous Cell Carcinoma in Correlation With Lymph Node Metastasis. Anticancer research. 2019;39(11):6307-16.

32. Harris K, Gelberg HB, Kiupel M, Helfand SC. Immunohistochemical Features of Epithelial-Mesenchymal Transition in Feline Oral Squamous Cell Carcinoma. Veterinary Pathology. 2019;56(6):826-39.

**Tables**

Due to technical limitations, table 1-2 is only available as a download in the Supplemental Files section.